News & Resources

Pharmacyclics Completes $57.1 Million Registered Direct Offering

June 17, 2011

Olshan’s client Pharmacyclics, Inc., a NASDAQ-listed clinical-stage biopharmaceutical company, announced that it completed a $57.1 million registered direct offering of its common stock.

Adam W. Finerman, Jonathan H. Deblinger and Michael D. DeDonato comprise the Olshan team that represented Pharmacyclics in this matter.